Clyde Wright
Concepts (374)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acetaminophen | 16 | 2026 | 264 | 7.680 |
Why?
| | Bronchopulmonary Dysplasia | 21 | 2024 | 410 | 7.000 |
Why?
| | NF-kappa B | 23 | 2024 | 661 | 6.930 |
Why?
| | Respiratory Distress Syndrome, Newborn | 12 | 2023 | 106 | 6.610 |
Why?
| | Endotoxemia | 10 | 2024 | 87 | 5.950 |
Why?
| | Pulmonary Surfactants | 10 | 2023 | 102 | 5.420 |
Why?
| | I-kappa B Proteins | 13 | 2022 | 74 | 4.470 |
Why?
| | Liver | 18 | 2026 | 1884 | 4.150 |
Why?
| | Ductus Arteriosus, Patent | 8 | 2024 | 50 | 3.550 |
Why?
| | Continuous Positive Airway Pressure | 12 | 2022 | 88 | 3.540 |
Why?
| | Immunity, Innate | 11 | 2026 | 846 | 3.250 |
Why?
| | Lung | 21 | 2026 | 4108 | 3.140 |
Why?
| | Lung Injury | 7 | 2022 | 237 | 2.940 |
Why?
| | Infant, Premature, Diseases | 5 | 2021 | 111 | 2.620 |
Why?
| | Infant, Newborn | 47 | 2026 | 6424 | 2.550 |
Why?
| | Signal Transduction | 21 | 2026 | 5221 | 2.530 |
Why?
| | Noninvasive Ventilation | 5 | 2022 | 62 | 2.410 |
Why?
| | Infant, Premature | 15 | 2024 | 611 | 2.350 |
Why?
| | Hyperoxia | 7 | 2017 | 99 | 1.810 |
Why?
| | Transcription Factor RelA | 4 | 2024 | 85 | 1.760 |
Why?
| | Animals, Newborn | 13 | 2024 | 901 | 1.690 |
Why?
| | Surface-Active Agents | 8 | 2023 | 92 | 1.660 |
Why?
| | Infant, Extremely Premature | 8 | 2024 | 67 | 1.650 |
Why?
| | Mice, Inbred ICR | 12 | 2021 | 113 | 1.630 |
Why?
| | Toll-Like Receptor 9 | 2 | 2026 | 37 | 1.570 |
Why?
| | Ibuprofen | 5 | 2024 | 84 | 1.430 |
Why?
| | Lipopolysaccharides | 9 | 2024 | 863 | 1.380 |
Why?
| | Neonatology | 3 | 2025 | 28 | 1.360 |
Why?
| | Biological Products | 3 | 2021 | 251 | 1.350 |
Why?
| | Toll-Like Receptor 4 | 3 | 2023 | 276 | 1.340 |
Why?
| | Chemical and Drug Induced Liver Injury | 2 | 2022 | 139 | 1.310 |
Why?
| | Oxygen | 6 | 2022 | 995 | 1.260 |
Why?
| | Apoptosis | 6 | 2024 | 2430 | 1.240 |
Why?
| | Macrophages | 7 | 2020 | 1510 | 1.210 |
Why?
| | Mice | 32 | 2026 | 18329 | 1.170 |
Why?
| | Animals | 43 | 2026 | 38030 | 1.120 |
Why?
| | Evidence-Based Medicine | 4 | 2021 | 729 | 1.110 |
Why?
| | Inflammation | 5 | 2024 | 2877 | 1.100 |
Why?
| | Airway Extubation | 2 | 2020 | 60 | 1.100 |
Why?
| | NF-kappa B p50 Subunit | 4 | 2023 | 22 | 1.090 |
Why?
| | Fetal Growth Retardation | 6 | 2026 | 587 | 1.050 |
Why?
| | Tumor Necrosis Factor-alpha | 5 | 2024 | 1217 | 1.020 |
Why?
| | Infant, Newborn, Diseases | 2 | 2019 | 113 | 0.950 |
Why?
| | Mice, Inbred C57BL | 14 | 2026 | 5988 | 0.930 |
Why?
| | Cytochrome P-450 CYP2E1 | 5 | 2025 | 30 | 0.930 |
Why?
| | Pregnancy | 17 | 2026 | 7180 | 0.910 |
Why?
| | Humans | 72 | 2026 | 144261 | 0.850 |
Why?
| | Transcription Factor AP-1 | 1 | 2024 | 79 | 0.810 |
Why?
| | Disease Models, Animal | 14 | 2026 | 4556 | 0.800 |
Why?
| | Physician's Role | 2 | 2021 | 218 | 0.770 |
Why?
| | Gene Expression Regulation | 8 | 2021 | 2603 | 0.770 |
Why?
| | Acute Lung Injury | 1 | 2026 | 302 | 0.750 |
Why?
| | Interleukin-1alpha | 2 | 2020 | 57 | 0.740 |
Why?
| | Fetus | 5 | 2026 | 803 | 0.710 |
Why?
| | Interleukin-1beta | 3 | 2020 | 395 | 0.700 |
Why?
| | Premature Birth | 3 | 2022 | 380 | 0.700 |
Why?
| | Gene Expression Regulation, Enzymologic | 2 | 2021 | 269 | 0.690 |
Why?
| | Streptozocin | 1 | 2021 | 21 | 0.690 |
Why?
| | Selenoproteins | 1 | 2020 | 7 | 0.670 |
Why?
| | Caloric Restriction | 4 | 2026 | 127 | 0.640 |
Why?
| | Cyclooxygenase Inhibitors | 2 | 2024 | 81 | 0.630 |
Why?
| | Monocytes | 1 | 2023 | 538 | 0.630 |
Why?
| | Ovarian Follicle | 1 | 2020 | 73 | 0.620 |
Why?
| | Chorioamnionitis | 1 | 2020 | 45 | 0.620 |
Why?
| | Oxidative Stress | 3 | 2017 | 1339 | 0.610 |
Why?
| | Mice, Knockout | 5 | 2026 | 3119 | 0.590 |
Why?
| | Acidosis | 1 | 2020 | 105 | 0.590 |
Why?
| | Uterus | 1 | 2020 | 226 | 0.580 |
Why?
| | Emphysema | 1 | 2019 | 100 | 0.570 |
Why?
| | Oximetry | 2 | 2017 | 126 | 0.570 |
Why?
| | Inflammation Mediators | 3 | 2019 | 508 | 0.550 |
Why?
| | I-kappa B Kinase | 2 | 2021 | 51 | 0.550 |
Why?
| | Interferon-beta | 1 | 2018 | 92 | 0.550 |
Why?
| | Calcium Signaling | 1 | 2020 | 251 | 0.540 |
Why?
| | Gestational Age | 4 | 2024 | 975 | 0.540 |
Why?
| | Treatment Failure | 2 | 2019 | 363 | 0.540 |
Why?
| | Sugars | 1 | 2018 | 41 | 0.530 |
Why?
| | Beverages | 1 | 2018 | 69 | 0.520 |
Why?
| | Mediastinal Emphysema | 1 | 2017 | 9 | 0.510 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 257 | 0.510 |
Why?
| | Respiration, Artificial | 5 | 2022 | 707 | 0.510 |
Why?
| | Respiration | 2 | 2018 | 206 | 0.510 |
Why?
| | Gene Expression | 3 | 2024 | 1487 | 0.510 |
Why?
| | Male | 29 | 2026 | 72035 | 0.500 |
Why?
| | Peer Review, Research | 1 | 2017 | 36 | 0.500 |
Why?
| | Standard of Care | 1 | 2017 | 80 | 0.490 |
Why?
| | Insulin-Secreting Cells | 1 | 2021 | 387 | 0.490 |
Why?
| | Infant, Small for Gestational Age | 1 | 2017 | 109 | 0.490 |
Why?
| | Respiratory System | 1 | 2017 | 149 | 0.480 |
Why?
| | Immune Tolerance | 1 | 2018 | 379 | 0.480 |
Why?
| | Asphyxia Neonatorum | 1 | 2016 | 18 | 0.470 |
Why?
| | Intensive Care Units, Neonatal | 4 | 2022 | 279 | 0.460 |
Why?
| | Cyclooxygenase 2 | 1 | 2016 | 165 | 0.460 |
Why?
| | Nitric Oxide | 3 | 2019 | 897 | 0.440 |
Why?
| | Fellowships and Scholarships | 1 | 2019 | 355 | 0.440 |
Why?
| | Milk, Human | 1 | 2017 | 172 | 0.440 |
Why?
| | Child Advocacy | 2 | 2005 | 32 | 0.430 |
Why?
| | Hypothermia, Induced | 1 | 2016 | 96 | 0.430 |
Why?
| | Infant | 11 | 2026 | 10022 | 0.420 |
Why?
| | Hepatocytes | 4 | 2026 | 221 | 0.420 |
Why?
| | Female | 31 | 2026 | 77976 | 0.420 |
Why?
| | Fetal Diseases | 1 | 2016 | 191 | 0.420 |
Why?
| | NF-KappaB Inhibitor alpha | 4 | 2020 | 49 | 0.410 |
Why?
| | Intestinal Atresia | 1 | 2014 | 17 | 0.410 |
Why?
| | Cell Cycle Proteins | 1 | 2018 | 628 | 0.410 |
Why?
| | Endothelin-1 | 1 | 2015 | 184 | 0.410 |
Why?
| | Calcium | 1 | 2020 | 1182 | 0.410 |
Why?
| | Interleukin-6 | 3 | 2025 | 780 | 0.410 |
Why?
| | Sex Characteristics | 1 | 2019 | 789 | 0.400 |
Why?
| | Ethics Committees, Research | 1 | 2013 | 41 | 0.390 |
Why?
| | MicroRNAs | 3 | 2024 | 700 | 0.390 |
Why?
| | Infant, Very Low Birth Weight | 1 | 2013 | 73 | 0.390 |
Why?
| | Resuscitation | 1 | 2016 | 302 | 0.380 |
Why?
| | Cytomegalovirus Infections | 1 | 2015 | 206 | 0.380 |
Why?
| | Visual Perception | 1 | 2015 | 183 | 0.380 |
Why?
| | Intestine, Small | 1 | 2014 | 166 | 0.380 |
Why?
| | Pediatrics | 3 | 2005 | 1112 | 0.360 |
Why?
| | Abnormalities, Multiple | 1 | 2014 | 197 | 0.360 |
Why?
| | Fibroblasts | 3 | 2015 | 1032 | 0.360 |
Why?
| | Catheterization, Peripheral | 1 | 2013 | 117 | 0.360 |
Why?
| | Phospholipids | 1 | 2013 | 211 | 0.360 |
Why?
| | Respiration Disorders | 1 | 2012 | 77 | 0.350 |
Why?
| | Urinary Bladder | 1 | 2014 | 194 | 0.350 |
Why?
| | Fetal Blood | 2 | 2024 | 342 | 0.350 |
Why?
| | Colon | 1 | 2014 | 304 | 0.340 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2018 | 1705 | 0.340 |
Why?
| | Biomarkers | 3 | 2024 | 4254 | 0.330 |
Why?
| | Clinical Competence | 1 | 2019 | 1241 | 0.330 |
Why?
| | Microcirculation | 1 | 2010 | 138 | 0.320 |
Why?
| | Neuropsychological Tests | 1 | 2015 | 1129 | 0.310 |
Why?
| | Patient Safety | 1 | 2013 | 347 | 0.310 |
Why?
| | Nitric Oxide Synthase Type II | 2 | 2021 | 162 | 0.310 |
Why?
| | RAW 264.7 Cells | 2 | 2020 | 50 | 0.300 |
Why?
| | Glycolysis | 2 | 2021 | 339 | 0.300 |
Why?
| | Cells, Cultured | 5 | 2019 | 4146 | 0.300 |
Why?
| | Analgesics, Non-Narcotic | 3 | 2024 | 123 | 0.290 |
Why?
| | Cell Line | 4 | 2017 | 2879 | 0.290 |
Why?
| | Body Mass Index | 1 | 2017 | 2420 | 0.280 |
Why?
| | Indomethacin | 3 | 2024 | 76 | 0.280 |
Why?
| | Hydrocortisone | 2 | 2020 | 304 | 0.270 |
Why?
| | Curriculum | 2 | 2005 | 1057 | 0.270 |
Why?
| | Cytokines | 3 | 2023 | 2061 | 0.250 |
Why?
| | SOXC Transcription Factors | 1 | 2026 | 8 | 0.250 |
Why?
| | Cognition | 1 | 2015 | 1258 | 0.240 |
Why?
| | Endothelium, Vascular | 1 | 2013 | 963 | 0.240 |
Why?
| | Intercellular Adhesion Molecule-1 | 2 | 2020 | 138 | 0.240 |
Why?
| | Gene Silencing | 2 | 2021 | 205 | 0.240 |
Why?
| | Gluconeogenesis | 1 | 2026 | 83 | 0.230 |
Why?
| | Neonatologists | 1 | 2025 | 9 | 0.230 |
Why?
| | Glucagon | 1 | 2026 | 112 | 0.220 |
Why?
| | History, 20th Century | 2 | 2017 | 324 | 0.220 |
Why?
| | Biological Evolution | 1 | 2009 | 488 | 0.220 |
Why?
| | Cell Survival | 3 | 2021 | 1098 | 0.220 |
Why?
| | Gene Expression Regulation, Developmental | 2 | 2020 | 905 | 0.220 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2025 | 95 | 0.220 |
Why?
| | Biliary Atresia | 1 | 2026 | 157 | 0.220 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2025 | 139 | 0.210 |
Why?
| | Endothelial Cells | 1 | 2010 | 869 | 0.210 |
Why?
| | Neovascularization, Physiologic | 1 | 2026 | 194 | 0.210 |
Why?
| | Patient Advocacy | 1 | 2005 | 73 | 0.210 |
Why?
| | Internship and Residency | 2 | 2005 | 1255 | 0.210 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 2024 | 55 | 0.210 |
Why?
| | Cell Nucleus | 2 | 2019 | 618 | 0.210 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2024 | 72 | 0.200 |
Why?
| | RNA, Messenger | 4 | 2024 | 2829 | 0.200 |
Why?
| | STAT3 Transcription Factor | 1 | 2025 | 207 | 0.200 |
Why?
| | Trophoblasts | 1 | 2026 | 216 | 0.200 |
Why?
| | Research Personnel | 1 | 2025 | 183 | 0.200 |
Why?
| | Toll-Like Receptor 1 | 1 | 2023 | 13 | 0.200 |
Why?
| | Zymosan | 1 | 2023 | 39 | 0.200 |
Why?
| | Intensive Care, Neonatal | 1 | 2023 | 42 | 0.190 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2023 | 87 | 0.190 |
Why?
| | Infant, Low Birth Weight | 1 | 2023 | 153 | 0.180 |
Why?
| | Sheep | 2 | 2026 | 880 | 0.180 |
Why?
| | Amino Acids | 1 | 2026 | 521 | 0.180 |
Why?
| | Ligation | 1 | 2022 | 92 | 0.180 |
Why?
| | Age Factors | 2 | 2020 | 3313 | 0.180 |
Why?
| | Toll-Like Receptors | 1 | 2023 | 194 | 0.180 |
Why?
| | Morbidity | 2 | 2021 | 323 | 0.180 |
Why?
| | Hernias, Diaphragmatic, Congenital | 1 | 2024 | 219 | 0.170 |
Why?
| | Hepatic Veins | 1 | 2021 | 32 | 0.170 |
Why?
| | Dyspnea | 1 | 2023 | 251 | 0.170 |
Why?
| | Dilatation | 1 | 2022 | 72 | 0.170 |
Why?
| | Insulinoma | 1 | 2021 | 27 | 0.170 |
Why?
| | Chemokine CXCL10 | 1 | 2021 | 39 | 0.170 |
Why?
| | Feces | 1 | 2024 | 513 | 0.170 |
Why?
| | Transcription Factors | 1 | 2009 | 1739 | 0.170 |
Why?
| | Vascular Malformations | 1 | 2021 | 50 | 0.170 |
Why?
| | Glutathione Peroxidase | 1 | 2020 | 39 | 0.170 |
Why?
| | TNF Receptor-Associated Factor 1 | 1 | 2020 | 8 | 0.160 |
Why?
| | C-Reactive Protein | 1 | 2023 | 416 | 0.160 |
Why?
| | Selenium | 1 | 2020 | 49 | 0.160 |
Why?
| | Ventilator Weaning | 1 | 2020 | 39 | 0.160 |
Why?
| | Chemokine CCL3 | 1 | 2020 | 26 | 0.160 |
Why?
| | Portal Vein | 1 | 2021 | 114 | 0.160 |
Why?
| | Calcineurin Inhibitors | 1 | 2020 | 69 | 0.160 |
Why?
| | Oxidative Phosphorylation | 1 | 2021 | 210 | 0.150 |
Why?
| | Intermittent Positive-Pressure Ventilation | 1 | 2019 | 12 | 0.150 |
Why?
| | Chelating Agents | 1 | 2020 | 70 | 0.150 |
Why?
| | Homeostasis | 1 | 2024 | 640 | 0.150 |
Why?
| | Oligodeoxyribonucleotides | 1 | 2020 | 141 | 0.150 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2021 | 198 | 0.150 |
Why?
| | Norepinephrine | 1 | 2020 | 196 | 0.150 |
Why?
| | Primary Cell Culture | 1 | 2020 | 173 | 0.150 |
Why?
| | Proteolysis | 1 | 2020 | 173 | 0.150 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2022 | 338 | 0.150 |
Why?
| | Chemokine CXCL1 | 1 | 2019 | 76 | 0.150 |
Why?
| | Interferon Regulatory Factor-3 | 1 | 2018 | 16 | 0.140 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2019 | 120 | 0.140 |
Why?
| | Consensus | 1 | 2021 | 488 | 0.140 |
Why?
| | Biomedical Research | 1 | 2025 | 709 | 0.140 |
Why?
| | Mitochondria | 1 | 2025 | 983 | 0.140 |
Why?
| | Cytosol | 1 | 2019 | 227 | 0.140 |
Why?
| | Spleen | 1 | 2020 | 508 | 0.140 |
Why?
| | STAT1 Transcription Factor | 1 | 2018 | 68 | 0.140 |
Why?
| | Morphogenesis | 1 | 2019 | 173 | 0.140 |
Why?
| | Delivery Rooms | 1 | 2018 | 9 | 0.140 |
Why?
| | Weight Gain | 2 | 2023 | 556 | 0.140 |
Why?
| | Receptors, CCR2 | 1 | 2018 | 39 | 0.140 |
Why?
| | Receptor, Serotonin, 5-HT2A | 1 | 2018 | 18 | 0.140 |
Why?
| | Rotation | 1 | 2018 | 121 | 0.130 |
Why?
| | Protective Agents | 1 | 2018 | 42 | 0.130 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2024 | 674 | 0.130 |
Why?
| | Pulmonary Ventilation | 1 | 2018 | 83 | 0.130 |
Why?
| | Overnutrition | 1 | 2017 | 30 | 0.130 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2018 | 150 | 0.130 |
Why?
| | Hypertension, Pulmonary | 2 | 2019 | 1980 | 0.130 |
Why?
| | Ductus Arteriosus | 1 | 2017 | 72 | 0.130 |
Why?
| | Pennsylvania | 1 | 2017 | 136 | 0.130 |
Why?
| | Parturition | 1 | 2017 | 68 | 0.130 |
Why?
| | Disease Susceptibility | 1 | 2018 | 346 | 0.120 |
Why?
| | Calibration | 1 | 2017 | 151 | 0.120 |
Why?
| | Protective Factors | 1 | 2016 | 99 | 0.120 |
Why?
| | Conservative Treatment | 1 | 2017 | 44 | 0.120 |
Why?
| | Physicians | 1 | 2025 | 938 | 0.120 |
Why?
| | Gastrointestinal Microbiome | 1 | 2024 | 771 | 0.120 |
Why?
| | Positive-Pressure Respiration | 1 | 2017 | 112 | 0.120 |
Why?
| | History, 21st Century | 1 | 2017 | 219 | 0.120 |
Why?
| | RNA, Small Interfering | 2 | 2016 | 634 | 0.120 |
Why?
| | Primary Prevention | 1 | 2018 | 219 | 0.120 |
Why?
| | Health Status Disparities | 1 | 2019 | 321 | 0.120 |
Why?
| | Vascular Remodeling | 1 | 2018 | 204 | 0.120 |
Why?
| | Up-Regulation | 1 | 2019 | 851 | 0.120 |
Why?
| | Time-to-Treatment | 1 | 2018 | 240 | 0.120 |
Why?
| | Cholestasis | 1 | 2018 | 219 | 0.110 |
Why?
| | Macaca mulatta | 1 | 2016 | 191 | 0.110 |
Why?
| | Precision Medicine | 1 | 2019 | 456 | 0.110 |
Why?
| | Cell Proliferation | 3 | 2011 | 2494 | 0.110 |
Why?
| | Adult | 6 | 2025 | 40262 | 0.110 |
Why?
| | Administration, Oral | 1 | 2017 | 847 | 0.110 |
Why?
| | Nuclear Receptor Subfamily 1, Group D, Member 1 | 1 | 2014 | 3 | 0.110 |
Why?
| | Periodicals as Topic | 1 | 2017 | 203 | 0.100 |
Why?
| | Prune Belly Syndrome | 1 | 2014 | 8 | 0.100 |
Why?
| | Body Composition | 1 | 2018 | 704 | 0.100 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2014 | 85 | 0.100 |
Why?
| | Placenta | 3 | 2026 | 780 | 0.100 |
Why?
| | Interleukins | 1 | 2015 | 248 | 0.100 |
Why?
| | Cell Line, Tumor | 1 | 2021 | 3539 | 0.100 |
Why?
| | Syndrome | 1 | 2014 | 380 | 0.100 |
Why?
| | Breast Feeding | 1 | 2017 | 448 | 0.100 |
Why?
| | Practice Guidelines as Topic | 1 | 2021 | 1559 | 0.100 |
Why?
| | Kidney | 1 | 2020 | 1495 | 0.090 |
Why?
| | Child | 4 | 2018 | 22537 | 0.090 |
Why?
| | Pilot Projects | 1 | 2018 | 1867 | 0.090 |
Why?
| | Brain Injuries | 1 | 2017 | 506 | 0.090 |
Why?
| | Predictive Value of Tests | 1 | 2018 | 2111 | 0.090 |
Why?
| | Hydrogen Peroxide | 1 | 2014 | 336 | 0.090 |
Why?
| | Rats | 2 | 2013 | 5592 | 0.090 |
Why?
| | Transcriptome | 1 | 2019 | 1044 | 0.090 |
Why?
| | Culture Media, Serum-Free | 1 | 2012 | 42 | 0.090 |
Why?
| | Gene Knock-In Techniques | 1 | 2012 | 61 | 0.090 |
Why?
| | Risk Assessment | 2 | 2019 | 3637 | 0.090 |
Why?
| | Cell Line, Transformed | 1 | 2012 | 140 | 0.090 |
Why?
| | Child, Preschool | 3 | 2026 | 11774 | 0.090 |
Why?
| | Software | 1 | 2017 | 690 | 0.090 |
Why?
| | Mice, Mutant Strains | 1 | 2012 | 299 | 0.090 |
Why?
| | CCAAT-Enhancer-Binding Protein-alpha | 1 | 2011 | 17 | 0.090 |
Why?
| | Radiography | 1 | 2014 | 842 | 0.090 |
Why?
| | Retinopathy of Prematurity | 1 | 2013 | 179 | 0.080 |
Why?
| | Superoxide Dismutase | 1 | 2013 | 301 | 0.080 |
Why?
| | Longitudinal Studies | 1 | 2018 | 2926 | 0.080 |
Why?
| | Cohort Studies | 2 | 2019 | 5935 | 0.080 |
Why?
| | Mice, Transgenic | 1 | 2015 | 2182 | 0.080 |
Why?
| | Protoporphyrins | 1 | 2009 | 14 | 0.080 |
Why?
| | Caspase 3 | 1 | 2010 | 238 | 0.080 |
Why?
| | Cyclin D1 | 1 | 2009 | 61 | 0.080 |
Why?
| | Diagnosis, Differential | 1 | 2014 | 1487 | 0.080 |
Why?
| | Circadian Rhythm | 1 | 2014 | 513 | 0.070 |
Why?
| | Heme Oxygenase-1 | 1 | 2009 | 74 | 0.070 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2516 | 0.070 |
Why?
| | Antioxidants | 1 | 2013 | 549 | 0.070 |
Why?
| | Luciferases | 1 | 2008 | 152 | 0.070 |
Why?
| | Pulmonary Alveoli | 1 | 2011 | 383 | 0.070 |
Why?
| | Tyrosine | 1 | 2008 | 221 | 0.070 |
Why?
| | Genes, Reporter | 1 | 2008 | 275 | 0.070 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2008 | 381 | 0.070 |
Why?
| | Amino Acid Substitution | 1 | 2008 | 304 | 0.070 |
Why?
| | Blood Glucose | 1 | 2018 | 2312 | 0.070 |
Why?
| | Gene Expression Profiling | 2 | 2012 | 1782 | 0.070 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2009 | 182 | 0.060 |
Why?
| | Rats, Sprague-Dawley | 1 | 2013 | 2525 | 0.060 |
Why?
| | Aging | 1 | 2017 | 1964 | 0.060 |
Why?
| | United States | 3 | 2025 | 15876 | 0.060 |
Why?
| | Transfection | 1 | 2008 | 938 | 0.060 |
Why?
| | Risk Factors | 2 | 2019 | 10699 | 0.060 |
Why?
| | Enzyme Inhibitors | 1 | 2009 | 824 | 0.060 |
Why?
| | Placentation | 1 | 2026 | 53 | 0.060 |
Why?
| | Recombinant Proteins | 1 | 2008 | 1367 | 0.060 |
Why?
| | Base Sequence | 1 | 2008 | 2187 | 0.060 |
Why?
| | Research Support as Topic | 1 | 2025 | 79 | 0.060 |
Why?
| | Wisconsin | 1 | 2005 | 99 | 0.050 |
Why?
| | Cell Differentiation | 2 | 2011 | 2048 | 0.050 |
Why?
| | Pregnancy Trimester, Third | 1 | 2024 | 115 | 0.050 |
Why?
| | Phosphorylation | 1 | 2008 | 1732 | 0.050 |
Why?
| | Amniotic Fluid | 1 | 2024 | 79 | 0.050 |
Why?
| | Career Choice | 1 | 2025 | 236 | 0.050 |
Why?
| | Prenatal Diagnosis | 1 | 2024 | 195 | 0.050 |
Why?
| | Job Satisfaction | 1 | 2025 | 240 | 0.050 |
Why?
| | Program Development | 1 | 2005 | 369 | 0.050 |
Why?
| | Diet, High-Fat | 1 | 2023 | 261 | 0.040 |
Why?
| | Data Collection | 1 | 2005 | 633 | 0.040 |
Why?
| | Child Health Services | 1 | 2004 | 185 | 0.040 |
Why?
| | Educational Measurement | 1 | 2005 | 325 | 0.040 |
Why?
| | DNA | 1 | 2008 | 1460 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2024 | 1044 | 0.040 |
Why?
| | Models, Biological | 1 | 2008 | 1820 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2023 | 557 | 0.040 |
Why?
| | Program Evaluation | 1 | 2005 | 946 | 0.040 |
Why?
| | Fetal Development | 1 | 2023 | 299 | 0.040 |
Why?
| | Education, Medical, Graduate | 1 | 2005 | 557 | 0.040 |
Why?
| | Infant, Extremely Low Birth Weight | 1 | 2019 | 24 | 0.040 |
Why?
| | Liver Transplantation | 1 | 2026 | 822 | 0.040 |
Why?
| | Disease Progression | 1 | 2026 | 2840 | 0.040 |
Why?
| | Caspases, Initiator | 1 | 2018 | 17 | 0.030 |
Why?
| | Liver X Receptors | 1 | 2018 | 30 | 0.030 |
Why?
| | Administration, Inhalation | 1 | 2019 | 574 | 0.030 |
Why?
| | Ketanserin | 1 | 2018 | 12 | 0.030 |
Why?
| | Glucose | 1 | 2023 | 1046 | 0.030 |
Why?
| | Serotonin Antagonists | 1 | 2018 | 30 | 0.030 |
Why?
| | Caspase 1 | 1 | 2018 | 148 | 0.030 |
Why?
| | Receptors, Interleukin-1 | 1 | 2018 | 213 | 0.030 |
Why?
| | Caspases | 1 | 2018 | 232 | 0.030 |
Why?
| | Parenteral Nutrition | 1 | 2018 | 105 | 0.030 |
Why?
| | Lipoproteins | 1 | 2018 | 163 | 0.030 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2018 | 139 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2024 | 3592 | 0.030 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2018 | 209 | 0.030 |
Why?
| | Bleomycin | 1 | 2018 | 253 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2019 | 358 | 0.030 |
Why?
| | Social Determinants of Health | 1 | 2019 | 299 | 0.030 |
Why?
| | Comet Assay | 1 | 2014 | 14 | 0.030 |
Why?
| | Surveys and Questionnaires | 1 | 2025 | 6021 | 0.020 |
Why?
| | Prospective Studies | 1 | 2024 | 7970 | 0.020 |
Why?
| | Proliferating Cell Nuclear Antigen | 1 | 2011 | 49 | 0.020 |
Why?
| | Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2011 | 49 | 0.020 |
Why?
| | DNA Damage | 1 | 2014 | 428 | 0.020 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2011 | 112 | 0.020 |
Why?
| | Binding Sites | 1 | 2014 | 1327 | 0.020 |
Why?
| | Tissue Distribution | 1 | 2011 | 327 | 0.020 |
Why?
| | Injections | 1 | 2011 | 196 | 0.020 |
Why?
| | Sp1 Transcription Factor | 1 | 2009 | 25 | 0.020 |
Why?
| | Early Growth Response Protein 1 | 1 | 2009 | 32 | 0.020 |
Why?
| | Hep G2 Cells | 1 | 2009 | 74 | 0.020 |
Why?
| | K562 Cells | 1 | 2009 | 93 | 0.020 |
Why?
| | Response Elements | 1 | 2009 | 89 | 0.020 |
Why?
| | Neoplasms, Experimental | 1 | 2009 | 173 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2009 | 765 | 0.020 |
Why?
| | Neovascularization, Pathologic | 1 | 2009 | 286 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2009 | 758 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2009 | 1253 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2024 | 17009 | 0.010 |
Why?
| | Epithelial Cells | 1 | 2011 | 1125 | 0.010 |
Why?
| | Middle Aged | 1 | 2025 | 35762 | 0.010 |
Why?
| | Time Factors | 1 | 2011 | 7155 | 0.010 |
Why?
|
|
Wright's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|